Median Duration of Response (DOR)

Among the patients who responded in DESTINY-Breast01 (n=111/184),

With ~15 months mDOR, ENHERTU monotherapy extended expectations of durability in patients who progressed on 2L anti-HER2 therapy1,a

Bar chart depicting 14.8 months median duration of response (95% CI: 13.8, 16.9) in ENHERTU patients who achieved an overall response rate (n=111) Bar chart depicting 14.8 months median duration of response (95% CI: 13.8, 16.9) in ENHERTU patients who achieved an overall response rate (n=111)

aMedian DOR based on Kaplan-Meier estimate. DOR based on a median duration of follow-up of 11.1 months.1

DESTINY-Breast01
follow-up data

(June 2020 data cutoff)
Originally presented at SABCS 2020 with an encore at Miami Breast 2021

View Additional Data bold-arrow
Ready to learn more about ENHERTU?
2L, second line; CI, confidence interval; HER2, human epidermal growth factor receptor 2; mBC, metastatic breast cancer; mDOR, median duration of response.